<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928459</url>
  </required_header>
  <id_info>
    <org_study_id>CBGJ398X2102</org_study_id>
    <nct_id>NCT01928459</nct_id>
  </id_info>
  <brief_title>Phase 1b Trial of BGJ398/BYL719 in Solid Tumors</brief_title>
  <official_title>A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose
      tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This dose escalation/dose expansion study will evaluate the combination of orally
      administered BGJ398 in combination with orally administered BYL719. During the dose
      escalation part, the MTD of the combination will be determined in patients whose advanced or
      metastatic tumors express mutations to PIK3CA. Once the MTD has been determined, the
      expansion part will begin. Patients will be addd to one of three arms based on the disease
      type and genetic changes. Patients with metastatic colorectal cancer are not eligible for
      participation in the expansion part.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719</measure>
    <time_frame>Approximately 8 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BGJ398/BYL719 combination at the recommended dose for expansion (RDE)</measure>
    <time_frame>Every 28 days from baseline visit until end of study visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Every two months from the date of baseline CT scan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719; Overall response rate = complete response + partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Every two months from the date of baseline CT scan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time vs. concentration profile of BGJ398 and BYL719</measure>
    <time_frame>Every 28 days for up to 10 cycles</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of BGJ398 with BYL719</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Advanced Solid Tumors,</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Metastatic breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid tumor arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid tumor arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398</intervention_name>
    <description>BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.</description>
    <arm_group_label>Metastatic breast cancer</arm_group_label>
    <arm_group_label>Solid tumor arm 1</arm_group_label>
    <arm_group_label>Solid tumor arm 2</arm_group_label>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719 will be administered orally once daily on each day of the 28-day cycle.</description>
    <arm_group_label>Metastatic breast cancer</arm_group_label>
    <arm_group_label>Solid tumor arm 1</arm_group_label>
    <arm_group_label>Solid tumor arm 2</arm_group_label>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed advanced or metastatic solid tumors who have
             failed standard therapy or for whom no effective standard anti-cancer therapy exists

          -  Documented PIK3CA mutations in all patients in dose escalation and expansion with or
             without documented genetic alterations in FGFR depending upon dose expansion cohort
             (either local or central determination)

          -  Measurable disease defined by RECIST v1.1

          -  ECOG performance status of ≤2

        Exclusion Criteria:

          -  Prior PI3Ki or selective FGFR inhibitor treatment (for patients enrolled to expansion
             part)

          -  Colorectal cancer (for patients enrolled to expansion part)

          -  Patients with diabetes mellitus requiring insulin treatment and/or with clinical
             signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of clinically
             significant gestational diabetes mellitus or documented steroid-induced diabetes
             mellitus

          -  Use of medications that increase serum levels of phosphorus and/or calcium

          -  Inorganic phosphorus outside of normal limits

          -  Total and ionized serum calcium outside of normal limits
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Moffitt 4</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Johnson</last_name>
      <phone>813-745-5434</phone>
      <email>matthew.johnson@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Amit Mahipal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center SC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Granche</last_name>
      <phone>734-232-0759</phone>
      <email>granche@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Rashmi Chugh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Dept of Onc</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly the Schneider</last_name>
      <phone>+1 313 576 8096</phone>
      <email>schneidk@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ulka M. Vaishampayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Onc Dept</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Nieman</last_name>
      <phone>314-362-7249</phone>
      <email>rnieman@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Craig X. Lockhart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Onc Dept</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald G. O'Neill, M.D.</last_name>
      <phone>646-227-3206</phone>
      <email>oneillg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>David G. Hyman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Dept of Onc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula J Halmon</last_name>
      <phone>615-343-0798</phone>
      <email>ursula.a.halmon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ingrid A. Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center SC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyson A DeSutter</last_name>
      <phone>210-450-5976</phone>
      <email>desutter@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>John Sarantopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 7, 2016</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGJ398, BYL719, advanced solid tumor, metastatic breast cancer, PK3CA, FGFR, fibroblast growth factor receptor,</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
